PERSPECTIVE THERAPEUTICS INC (CATX) Stock Price & Overview
NYSEARCA:CATX • US46489V3024
Current stock price
The current stock price of CATX is 4.41 USD. Today CATX is down by -0.23%. In the past month the price decreased by -13.53%. In the past year, price increased by 145%.
CATX Key Statistics
- Market Cap
- 502.343M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.40
- Dividend Yield
- N/A
CATX Stock Performance
CATX Stock Chart
CATX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CATX. When comparing the yearly performance of all stocks, CATX is one of the better performing stocks in the market, outperforming 95.62% of all stocks.
CATX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATX. The financial health of CATX is average, but there are quite some concerns on its profitability.
CATX Earnings
On March 16, 2026 CATX reported an EPS of -0.51 and a revenue of 43.00K. The company missed EPS expectations (-40.27% surprise) and missed revenue expectations (-80.45% surprise).
CATX Forecast & Estimates
20 analysts have analysed CATX and the average price target is 12.95 USD. This implies a price increase of 193.56% is expected in the next year compared to the current price of 4.41.
For the next year, analysts expect an EPS growth of 8.52% and a revenue growth -8.17% for CATX
CATX Groups
Sector & Classification
CATX Financial Highlights
Over the last trailing twelve months CATX reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS decreased by -66.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.89% | ||
| ROE | -43.68% | ||
| Debt/Equity | 0.01 |
CATX Ownership
CATX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CATX
Company Profile
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 163 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
IPO: 2002-05-31
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON US
Employees: 163
Phone: 18009279800
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
Can you describe the business of PERSPECTIVE THERAPEUTICS INC?
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 163 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Can you provide the latest stock price for PERSPECTIVE THERAPEUTICS INC?
The current stock price of CATX is 4.41 USD. The price decreased by -0.23% in the last trading session.
What is the dividend status of PERSPECTIVE THERAPEUTICS INC?
CATX does not pay a dividend.
How is the ChartMill rating for PERSPECTIVE THERAPEUTICS INC?
CATX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is CATX stock listed?
CATX stock is listed on the NYSE Arca exchange.
What is the GICS sector and industry of CATX stock?
PERSPECTIVE THERAPEUTICS INC (CATX) operates in the Health Care sector and the Biotechnology industry.
What is PERSPECTIVE THERAPEUTICS INC worth?
PERSPECTIVE THERAPEUTICS INC (CATX) has a market capitalization of 502.34M USD. This makes CATX a Small Cap stock.